Omar Veiseh:
Yesterday, Eli Lilly announced a definitive agreement to acquire Sigilon Therapeutics, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases. Sigilon Therapeutics was co-founded by Omar Veiseh, Associate Professor of Bioengineering and CPRIT Scholar in Cancer Research at Rice. Read more.
Glasscock School:
Kristen Schlatre is new asst dean for professional and corporate programs (Rice News)
Blog Categories